Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | DRD5 | P21918 | 1/20 | 0.37 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | PDE1A | P54750 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6371058 | 0.80 | ADORA1 (0.42) | ADORA1ADORA2BADORA2ALMNACYP1A2 | |
| SCHEMBL17604167 | 0.80 | PRMT5 (0.36) | ADORA1ADORA2BADORA2ALMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL17604355 | 0.79 | PRMT5 (0.35) | ADORA1ADORA2BADORA2APDE5APDE1A | |
| SCHEMBL6366943 | 0.79 | ADORA2A (0.38) | ADORA1ADORA2BADORA2APDE5APDE1A | |
| SCHEMBL6365300 | 0.77 | ADORA1 (0.41) | ADORA1ADORA2BADORA2ALMNACYP1A2 | |
| SCHEMBL6365678 | 0.76 | TSHR (0.39) | ADORA1ADORA2BADORA2ALMNACYP1A2 | |
| SCHEMBL6366291 | 0.74 | PDE9A (0.46) | ADORA1ADORA2BADORA2ALMNACYP1A2 | |
| SCHEMBL17604146 | 0.73 | ADORA1 (0.31) | ADORA1ADORA2BADORA2APDE5APDE1A | |
| SCHEMBL17604244 | 0.73 | ADORA1 (0.35) | ADORA1ADORA2BADORA2ALMNACYP1A2 | |
| SCHEMBL6368262 | 0.71 | CXCR2 (0.38) | ADORA2BADORA2ATSHRPDE5APDE1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6967204-B2 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | ADORA1 1339/4885ADORA2B 950/4885ADORA2A 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.